David Shaw’s Fate Therapeutics FATE Stock Holding History

David Shaw’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$1.94M	–	5449
2022 Q1	$1.94M	Buy	+50,000	New	+$1.94M	﹤0.01%	3333

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

David Shaw's FATE Position: Q2 2025 in Review

David Shaw sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 433,192 shares — an estimated $342K sold.

David Shaw first reported a position in FATE in Q1 2018 and held it in 20 quarters. The position peaked at $36M in Q4 2020. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

David Shaw reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
David Shaw sold 433,192 Fate Therapeutics shares in Q2 2025, an estimated $342K.
David Shaw first reported a position in Fate Therapeutics in Q1 2018 and held it in 20 quarters.
David Shaw's Fate Therapeutics position peaked at $36M in Q4 2020.
139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.